Trial · NCT04504916
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR)- Blinded Independent Central Review (BICR) | Zilovertamab Vedotin Q1/3W | 1.4 | 95% Confidence Interval 0.0 to 7.7 | Percentage of Participants | |
| Objective Response Rate (ORR)- Blinded Independent Central Review (BICR) | Zilovertamab Vedotin Q2/3W | 0.0 | 95% Confidence Interval NA to NA | Percentage of Participants | |
| ORR- Investigator Assessed | Zilovertamab Vedotin Q1/3W | 1.4 | 95% Confidence Interval 0.0 to 7.7 | Percentage of Participants | |
| ORR- Investigator Assessed | Zilovertamab Vedotin Q2/3W | 0.0 | 95% Confidence Interval NA to NA | Percentage of Participants | |
| Time to Response (TTR)- BICR | Zilovertamab Vedotin Q1/3W | 1.9 | Standard Deviation NA | Months | |
| Duration of Response (DOR)- BICR | Zilovertamab Vedotin Q1/3W | 1 | 95% Confidence Interval NA to NA | Months | |
| Progression-free Survival (PFS)- BICR | Zilovertamab Vedotin Q1/3W | 2.3 | 95% Confidence Interval 2.0 to 4.1 | Months | |
| Progression-free Survival (PFS)- BICR | Zilovertamab Vedotin Q2/3W | 1.9 | 95% Confidence Interval 1.7 to 2.1 | Months | |
| Time to Treatment Failure (TTF)- BICR | Zilovertamab Vedotin Q1/3W | 2.2 | 95% Confidence Interval 1.9 to 4.1 | Months | |
| Time to Treatment Failure (TTF)- BICR | Zilovertamab Vedotin Q2/3W | 1.9 | 95% Confidence Interval 1.7 to 2.1 | Months | |
| Overall Survival (OS) | Zilovertamab Vedotin Q1/3W | 8.3 | 95% Confidence Interval 5.2 to 10.3 | Months | |
| Overall Survival (OS) | Zilovertamab Vedotin Q2/3W | 5.5 | 95% Confidence Interval 4.4 to 11.0 | Months | |
| Number of Participants Who Experienced an Adverse Event (AE) | Zilovertamab Vedotin Q1/3W | 70 | Participants | ||
| Number of Participants Who Experienced an Adverse Event (AE) | Zilovertamab Vedotin Q2/3W | 32 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | Zilovertamab Vedotin Q1/3W | 7 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | Zilovertamab Vedotin Q2/3W | 6 | Participants | ||
| Maximum Plasma Concentration (Cmax) of Zilovertamab Vedotin-Q1/3W Dosing Schedule | Zilovertamab Vedotin Q1/3W | 53.4 | Geometric Coefficient of Variation 20.5 | μg/mL | |
| Cmax of Total Antibody-Q1/3W Dosing Schedule | Zilovertamab Vedotin Q1/3W | 51.2 | Geometric Coefficient of Variation 23.3 | μg/mL | |
| Cmax of MMAE-Q1/3W Dosing Schedule | Zilovertamab Vedotin Q1/3W | 0.00393 | Geometric Coefficient of Variation 65.7 | μg/mL | |
| Area Under the Plasma Concentration-time Curve (AUC) 0-504hrs of Zilovertamab Vedotin- Q1/3W Dosing Schedule | Zilovertamab Vedotin Q1/3W | 4030 | Geometric Coefficient of Variation 27.3 | hr*μg/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04504916/results